ASCO 2023 | Resistance to ADCs in breast cancer and novel combination strategies

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, provides an overview of resistance mechanisms to antibody-drug conjugates (ADCs) in patients with breast cancer. Downregulation of receptors such as HER2, which is a target for trastuzumab deruxtecan, can induce resistance, and mutations in tumors can additionally result in resistance to the payload. Dr Hamilton also discusses promising combination strategies, where combining ADCs with endocrine therapies, immunotherapies, or PARP inhibitors may have a synergistic effect without a serious increase in toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.